Coronary Microvascular Disease: the Next Frontier in Ischemic Heart Disease

Поделиться
HTML-код
  • Опубликовано: 30 июл 2024
  • Marie Guerraty, MD, PhD, is currently an instructor in cardiovascular medicine ‪@pennmedicine‬.
    Objectives:
    1. Understand why Coronary Microvascular Disease (CMVD) is an important and prevalent clinical entity.
    2. Draw from existing genomic and developmental research to gain insight into CMVD.
    3. Understand how transcriptional coregulator Friend of GATA 2 (FOG2) may play a role in CMVD.
    Follow Yale Cardiovascular Medicine on Twitter: / yalecardiology
    Sign up for email updates: subscribe.yale.edu/
    0:00 Introduction
    2:24 Coronary Arterial Circulation
    7:23 CAD GWAS = Ischemic Heart Disease GWAS
    12:32 Phenome-Wide Association Study of non
    15:26 Discrete left heart catheterization
    16:44 Matched cohorts for deeper phenotypic
    24:34 Using CRISPR/Cas9 genome
    27:08 Angiogenic effects of
    33:37 TWIST1 in Smooth Muscle Cells
    38:00 TWIST1 Summary
    46:40 Acknowledgements

Комментарии • 3